UPDATE | July 6, 2017

Samsung Biologics informs you about the lawsuit against the Lonza

  • MAIL

On July 3, Samsung Biologics Co., Ltd. filed a petition with the Korean Intellectual Property Trial and Appeal Board, seeking to invalidate a Korean patent registered to Lonza Biologics PLC related to cell line development. 

 

According to the petition, the patent was granted in Korea in 2007, and its counterparts in the United States, Europe, and Japan were abandoned, withdrawn, or refused.


For more details, please refer the news coverage below:

http://pulsenews.co.kr/view.php?year=2017&no=454024

 

On July 3, Samsung Biologics Co., Ltd. filed a petition with the Korean Intellectual Property Trial and Appeal Board, seeking to invalidate a Korean patent registered to Lonza Biologics PLC related to cell line development. 

 

According to the petition, the patent was granted in Korea in 2007, and its counterparts in the United States, Europe, and Japan were abandoned, withdrawn, or refused.


For more details, please refer the news coverage below:

http://pulsenews.co.kr/view.php?year=2017&no=454024

 

Share article

  • MAIL

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required